239 related articles for article (PubMed ID: 19664243)
1. A tumor cord model for doxorubicin delivery and dose optimization in solid tumors.
Eikenberry S
Theor Biol Med Model; 2009 Aug; 6():16. PubMed ID: 19664243
[TBL] [Abstract][Full Text] [Related]
2. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.
El-Kareh AW; Secomb TW
Neoplasia; 2000; 2(4):325-38. PubMed ID: 11005567
[TBL] [Abstract][Full Text] [Related]
3. Mathematical modelling of drug transport and uptake in a realistic model of solid tumour.
Zhan W; Gedroyc W; Xu XY
Protein Pept Lett; 2014; 21(11):1146-56. PubMed ID: 25106906
[TBL] [Abstract][Full Text] [Related]
4. Image-based spatio-temporal model of drug delivery in a heterogeneous vasculature of a solid tumor - Computational approach.
Moradi Kashkooli F; Soltani M; Rezaeian M; Taatizadeh E; Hamedi MH
Microvasc Res; 2019 May; 123():111-124. PubMed ID: 30711547
[TBL] [Abstract][Full Text] [Related]
5. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat.
Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC
Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187
[TBL] [Abstract][Full Text] [Related]
6. A comparative study between conventional chemotherapy and photothermal activated nano-sized targeted drug delivery to solid tumor.
Kiani Shahvandi M; Souri M; Tavasoli S; Moradi Kashkooli F; Kar S; Soltani M
Comput Biol Med; 2023 Nov; 166():107574. PubMed ID: 37839220
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
8. Dendrimer Conjugation Enhances Tumor Penetration and Efficacy of Doxorubicin in Extracellular Matrix-Expressing 3D Lung Cancer Models.
Almuqbil RM; Heyder RS; Bielski ER; Durymanov M; Reineke JJ; da Rocha SRP
Mol Pharm; 2020 May; 17(5):1648-1662. PubMed ID: 32227969
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
11. Computational modeling to predict effect of treatment schedule on drug delivery to prostate in humans.
Hu L; Au JL; Wientjes MG
Clin Cancer Res; 2007 Feb; 13(4):1278-87. PubMed ID: 17317840
[TBL] [Abstract][Full Text] [Related]
12. Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature.
Liu Y; Kim YJ; Siriwon N; Rohrs JA; Yu Z; Wanga P
Biotechnol Bioeng; 2018 Jun; 115(6):1403-1415. PubMed ID: 29457630
[TBL] [Abstract][Full Text] [Related]
13. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
Curnis F; Sacchi A; Corti A
J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin.
Zhao N; Leng Q; Woodle MC; Mixson AJ
Biochem Biophys Res Commun; 2019 May; 513(1):242-247. PubMed ID: 30954222
[TBL] [Abstract][Full Text] [Related]
15. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
Twelves CJ; Dobbs NA; Aldhous M; Harper PG; Rubens RD; Richards MA
Cancer Chemother Pharmacol; 1991; 28(4):302-7. PubMed ID: 1879047
[TBL] [Abstract][Full Text] [Related]
18. A systematic study of temperature sensitive liposomal delivery of doxorubicin using a mathematical model.
Liu C; Xu XY
Comput Biol Med; 2015 May; 60():107-16. PubMed ID: 25817532
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
Cusack BJ; Young SP; Driskell J; Olson RD
Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
[TBL] [Abstract][Full Text] [Related]
20. Modeling localized delivery of Doxorubicin to the brain following focused ultrasound enhanced blood-brain barrier permeability.
Nhan T; Burgess A; Lilge L; Hynynen K
Phys Med Biol; 2014 Oct; 59(20):5987-6004. PubMed ID: 25230100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
